Status:
COMPLETED
Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
Lead Sponsor:
University of Utah
Conditions:
Thromboembolism
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery. The investigators hypothesize ...
Detailed Description
Venous thromboembolism (VTE) is a major contributor to maternal morbidity and mortality. The first two weeks postpartum are the highest risk period for VTE during pregnancy and the postpartum period. ...
Eligibility Criteria
Inclusion
- Cesarean delivery at the University of Utah Health
Exclusion
- Contraindication to anticoagulation
- Plan for therapeutic anticoagulation
- Known renal dysfunction (creatinine clearance \<30mL/minute)
- History of venous thromboembolism
- High risk thrombophilia
- Receipt of antepartum anticoagulation for \>2 weeks
Key Trial Info
Start Date :
October 11 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06118957
Start Date
October 11 2023
End Date
July 1 2024
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah
Salt Lake City, Utah, United States, 84132